Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) Invested Capital (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Invested Capital for 3 consecutive years, with $136.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital fell 23.38% to $136.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $136.7 million, a 23.38% decrease, with the full-year FY2024 number at $133.6 million, up 207.07% from a year prior.
  • Invested Capital was $136.7 million for Q3 2025 at Inhibrx Biosciences, down from $167.8 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $219.4 million in Q2 2024 to a low of -$24.8 million in Q2 2023.
  • A 3-year average of $118.9 million and a median of $135.2 million in 2024 define the central range for Invested Capital.
  • Biggest YoY gain for Invested Capital was 1569.23% in 2025; the steepest drop was 23.49% in 2025.
  • Inhibrx Biosciences' Invested Capital stood at $43.5 million in 2023, then surged by 207.07% to $133.6 million in 2024, then rose by 2.37% to $136.7 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Invested Capital are $136.7 million (Q3 2025), $167.8 million (Q2 2025), and $193.1 million (Q1 2025).